E-Selectin inhibitor– Pipeline Insight, 2024

E-Selectin inhibitor– Pipeline Insight, 2024

DelveInsight’s, “E-Selectin inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 7+ pipeline drugs in E-selectin inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

E-Selectin inhibitor Understanding

E-SELECTIN inhibitor: Overview

E-Selectin (CD62E or previously referred to as ELAM-1) is a 115 kDa, inducible endothelial cell surface molecule. Its expression on endothelial cells is transcriptionally upregulated by various proinflammatory substances such as IL-1, TNFα and lipopolysaccharide (LPS). Expression of E-selectin on the endothelium is a hallmark of inflammation. E-selectin has been chosen as a target for several therapeutic and medical imaging applications, based on its expression in the vicinity of inflammation, infection or cancer.

Structure- E-selectin is a transmembrane receptor of the selectin family that also contains L- and P-selectins. Two glycosylated forms of E-selectin are detected at 100 and 115 kDa. The primary structure of E-selectin contains several domains: an amino terminal lectin-like domain, followed by an epidermal growth factor (EGF)-like domain and six repeated motifs similar to those found in some complement-binding proteins.

Function – E-Selectin is involved in the accumulation process of blood leukocytes at sites of inflammation by mediating the adhesion of cells to the vascular lining. Adhesion molecules participate in the interaction between leukocytes and the endothelium and appear to be involved in the pathogenesis of atherosclerosis.

E-SELECTIN Inhibitors- In research studies, Inhibiting E-selectin attenuated inflammation in atherosclerotic plaques, likely by reducing leukocyte recruitment into plaques and by mitigating hematopoietic stem and progenitor cell activation in the spleen of mice with myocardial Infarction. Various strategies are studied to exploit and modulate E-selectin-mediated binding include blocking its interaction with its ligands, blocking its ligands and inhibiting the glycosyl transferases associated with biosynthesis of selectin carbohydrate binding determinants. These strategies could inhibit immune and cancer cell adhesion in inflammation and metastasis, respectively.

E-SELECTIN inhibitor Emerging Drugs Chapters

This segment of the E-SELECTIN inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

E-SELECTIN inhibitor Emerging Drugs

• Uproleselan: GlycoMimetics

A specific E-selectin antagonist, Uproleselan is an investigational small molecule with potential anti-thrombotic, antineoplastic and chemopotentiating activities. Uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. In combination with chemotherapy, uproleselan is used to treat patients with acute myeloid leukemia (AML) and potentially other hematologic cancers. The drug is currently in Phase III clinical studies for acute myeloid leukaemia.

• PF-07209326: Pfizer

PF-07209326 is an investigational biological therapy as E-Selectin antagonist. The therapy is currently in Phase I clinical development for the treatment of Sickle Cell disease.

Further product details are provided in the report……..

E-SELECTIN inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different E-SELECTIN inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on E-SELECTIN inhibitor

There are approx. 4+ key companies which are developing the E-SELECTIN inhibitor. The companies which have their E-SELECTIN inhibitor drug candidates in the most advanced stage, i.e. Phase III include, GlycoMimetics.

• Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

E-SELECTIN inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

E-SELECTIN inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses E-SELECTIN inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging E-SELECTIN inhibitor drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence E-SELECTIN inhibitor R&D. The therapies under development are focused on novel approaches for E-SELECTIN inhibitor.
• In January 2020, GlycoMimetics and Apollomics announce exclusive collaboration and license agreement to develop and commercialize uproleselan and GMI-1687 in Greater China. Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China. GlycoMimetics to receive an upfront cash payment with eligibility to receive development, regulatory, and sales-based milestones, and tiered royalties.

E-SELECTIN inhibitor Report Insights

• E-SELECTIN inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

E-SELECTIN inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing E-SELECTIN inhibitor drugs?
• How many E-SELECTIN inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for E-SELECTIN inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the E-SELECTIN inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for E-SELECTIN inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlycoMimetics
• Modus Therapeutics
• Pfizer

Key Products

• Uproleselan
• Rivipansel
• Sevuparin
• GMI-1687
• GMI-1359
• PF-07209326